Sahajanand Medical Technologies Ltd
Sahajanand Medical Technologies Credit Rating Upgraded by CRISIL
RATING
▲ Positive Development
LOW RISK
📅 Filed on BSE: 04 Nov 2026, 03:49 PM IST · BSE ID: 5ed31c86-7b4a-4308-920c-52d420d2034f
View Original BSE Filing (PDF)
💡
In Simple Terms
The company's ability to repay its bank loans has been rated higher, indicating improved financial health and business performance.
🤖 AI Summary
- Sahajanand Medical Technologies' long-term bank loan facilities upgraded to CRISIL A-/Stable.
- Rating upgrade covers Rs 300 Crores for the company and Rs 50 Crores for its subsidiary.
- Upgrade driven by 18% revenue growth to Rs 1,214 crore in fiscal 2026.
- Operating margin remained stable at 13.14% in fiscal 2026.
🔢 Key Numbers - exact figures from BSE filing, not rounded
Sahajanand Medical Technologies Limited Bank loan facilities
300 Crores
SMT Cardiovascular Private Limited Bank loan facilities
50 Crores
Sahajanand Medical Technologies Limited Long Term Rating
CRISIL A- /Stable
Upgraded from CRISIL BBB+/ Stable
Sahajanand Medical Technologies Limited Short Term Rating
CRISIL A2+
Upgraded from CRISIL A2
SMT Cardiovascular Private Limited Long Term Rating
CRISIL BBB+/Stable
Upgraded from CRISIL BBB/Stable
Sahajanand Medical Technologies Limited Operating revenue (FY26)
Rs 1,214 crore
Sahajanand Medical Technologies Limited Operating revenue (FY25)
Rs 1,032 crore
Sahajanand Medical Technologies Limited Operating margin (FY26)
13.14%
🏢 How This Affects the Company
An improved credit rating can enhance the company's access to debt financing and potentially lower borrowing costs, supporting future growth initiatives.
The upgrade reflects strengthening financial risk profile with sustained profitability and comfortable liquidity, supporting the company's balance sheet.
Not directly impacted by the credit rating change itself.
The upgrade suggests a reduction in credit risk associated with the company's bank loan facilities.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required by shareholders.
👤
Who Is Affected
All shareholders are indirectly affected by an improved credit profile that supports company stability and growth.
🔍
Management Signal
The upgrade signals management's success in strengthening the company's financial standing and operational performance.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List - track these upcoming events
Next quarter results announcement for FY27 performance.
Any further communication from CRISIL regarding rating rationale.
Company disclosures on debt financing activities.
LOW RISK
Credit rating upgrade by a reputable agency indicates a lower risk profile for lenders.
💡 Investor Takeaway
Sahajanand Medical Technologies' credit rating upgraded to CRISIL A-/Stable for Rs 300 crore facilities, reflecting 18% revenue growth to Rs 1,214 crore and stable operating margins of 13.14% in FY26.
⚖️ Strengths & Concerns
✅ Positives
- Operating revenue grew 18% to Rs 1,214 crore in fiscal 2026, up from Rs 1,032 crore in fiscal 2025.
- Operating margin sustained at 13.14% in fiscal 2026, stable over the past three fiscals.
⚠️ Concerns
- Susceptible to raw material prices and foreign exchange rate fluctuation.
- Exposure to regulatory risks and large working capital requirement.
📅 Company Track Record
Company recently completed its IPO in October 2026. This is the first credit rating intimation filed.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What is the new credit rating for Sahajanand Medical Technologies Limited?
Sahajanand Medical Technologies Limited's long-term bank loan facilities have been upgraded to CRISIL A-/Stable by CRISIL Ratings.
What is the rated amount for Sahajanand Medical Technologies Limited's bank loan facilities?
The rated amount for Sahajanand Medical Technologies Limited's bank loan facilities is Rs 300 Crores, enhanced from Rs 280 Crore.
What was Sahajanand Medical Technologies Limited's revenue in fiscal 2026?
Sahajanand Medical Technologies Limited's operating revenue grew 18% to Rs 1,214 crore in fiscal 2026.
What is the credit rating for SMT Cardiovascular Private Limited?
SMT Cardiovascular Private Limited's long-term bank loan facilities have been upgraded to CRISIL BBB+/Stable.
What factors led to the credit rating upgrade for Sahajanand Medical Technologies?
The upgrade reflects strengthening business risk profile, driven by growing scale of operations and sustained profitability, with a comfortable financial risk profile.
Questions based on this BSE filing only. For information purposes.